Phase I Clinical Trials of Cancer Drug ETS2101 Approved by Regulators
News Mar 29, 2012
e-Therapeutics plc has announced that regulatory agencies in the UK and the US have approved plans for phase I trials of the Company’s anti-cancer drug ETS2101 and that enrolment of patients into trials in these two countries will begin shortly.
A phase I trial in the UK will recruit patients with a variety of solid tumours, while a US investigator-led trial will enrol patients with primary or secondary brain cancers.
Further details of each trial will be provided when its first patient is treated.
Professor Malcolm Young, CEO of e-Therapeutics, said: “We remain on track to report the first data from cancer trials with ETS2101 and to advance three further drugs into the clinic by the end of this year.”
e-Therapeutics’ latest expectations for its other products are that ETX1153c (for C. difficile infection) will start phase I in Q2 or Q3, that ETS6103 (for major depressive disorder) will enter phase IIb in Q3 and that ETX1153a (for MRSA infection) will start phase I in Q4.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Their research revealed a promising strategy to develop a suitable agent. This novel concept could also be employed in the future rational design of drugs for the treatment of other diseases.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019